Eli Lilly and Company (NYSE:LLY) was a part of 100 hedge fund portfolios at the end of Q2 2024, down from 109 in the previous ...

The conventional wisdom is that there are two important aspects of timing in investing: when to buy a stock and when to sell ...

In an average of two studies, 38% of people who took Ebglyss achieved clear or almost-clear skin at 16 weeks, compared with 12% with placebo, Eli Lilly said. "Eli Lilly Gets FDA Approval for Eczema ...

The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker ...

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...

Shares of Eli Lilly & Co. LLY shed 1.21% to $923.71 Friday, on what proved to be an all-around positive trading session for ...

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 607.25% and ...

In a sweeping new lawsuit, over 900 people are claiming that Ozempic and other GLP-1 drugs caused them long-term ...

Nationally, the average cost of employer-sponsored health plans is expected to grow 9% next year if companies don’t find ways ...

Four years after launching a remote-controlled robotic laboratory in San Diego, Eli Lilly is shipping the operation overseas.

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- the year it was first approved in the U.S. -- some analysts predicted that ...